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Background: Tumor glycolysis is a target for cancer chemotherapy. Methylglyoxal (MG)
is a reactive metabolite formed mainly as a by-product in anaerobic glycolysis,
metabolized by glyoxalase 1 (Glo1) of the glyoxalase system. We investigated the role
of MG and Glo1 in cancer chemotherapy related in multidrug resistance (MDR).
Methods: Human Glo1 was overexpressed in HEK293 cells and the effect on anticancer
drug potency, drug-induced increase in MG and mechanism of cytotoxicity characterized.
Drug-induced increased MG and the mechanisms driving it were investigated and the
proteomic response to MG-induced cytotoxicity explored by high mass resolution
proteomics of cytoplasmic and other subcellular protein extracts. Glo1 expression data
of 1,040 human tumor cell lines and 7,489 tumors were examined for functional correlates
and impact of cancer patient survival.
Results: Overexpression of Glo1 decreased cytotoxicity of antitumor drugs, impairing
antiproliferative activity of alkylating agents, topoisomerase inhibitors, antitubulins, and
antimetabolites. Antitumor drugs increased MG to cytotoxic levels which contributed to
the cytotoxic, antiproliferative mechanism of action, consistent with Glo1-mediated MDR.
This was linked to off-target effects of drugs on glycolysis and was potentiated in hypoxia.
MG activated the intrinsic pathway of apoptosis, with decrease of mitochondrial and
spliceosomal proteins. Spliceosomal proteins were targets of MG modification.
Spliceosomal gene expression correlated positively with Glo1 in human tumor cell lines
and tumors. In clinical chemotherapy of breast cancer, increased expression of Glo1 wasNovember 2021 | Volume 11 | Article 7486981
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Frontiers in Oncology | www.frontiersin.orgassociated with decreased patient survival, with hazard ratio (HR) = 1.82 (logrank p <
0.001, n = 683) where upper quartile survival of patients was decreased by 64% with high
Glo1 expression.
Conclusions: We conclude that MG-mediated cytotoxicity contributes to the cancer
chemotherapeutic response and targets the spliceosome. High expression of Glo1
contributes to multidrug resistance by shielding the spliceosome from MG modification
and decreasing survival in the chemotherapy of breast cancer. Adjunct chemotherapy
with Glo1 inhibitor may improve treatment outcomes.Keywords: methylglyoxal, glyoxalase, cancer chemotherapy, multidrug resistance, proteomicsINTRODUCTION
Cancer is increasing in incidence and mortality worldwide (1).
Although improvements have been made in cancer
chemotherapy, drug resistance and the resulting decline in
effectiveness of drug treatment are considered to contribute to
90% of cancer-related deaths (2). Countering drug resistance
effectively is limited by its multifactorial mechanisms which may
change in relative importance as tumor stage advances. A
common feature of resistance to antiproliferative, cytotoxic
antitumor drugs is a cytoprotective response (3). Tumor cell
metabolism, including glycolysis, is an influential factor in
efficacy of cytotoxic antitumor drug (4), influencing response
and development of resistance (5, 6). Formation and metabolism
of the glycolysis-linked reactive metabolite, methylglyoxal (MG),
has a historical link to the glyoxalase pathway in tumor
metabolism, although its role in cancer treatment and
multidrug resistance (MDR) is not fully understood (7).
The glyoxalase system catalyzes the metabolism of the reactive
dicarbonyl metabolite, methylglyoxal (MG), to D-lactate. Glyoxalase
1 (Glo1) catalyzes the glutathione (GSH)-dependent metabolism of
MG to S-D-lactoylglutathione. Glyoxalase 2 (Glo2) catalyzes the
hydrolysis of S-D-lactoylglutathione to D-lactate, reforming GSH
consumed in the Glo1-catalyzed step (Figure 1A). MG is formed
spontaneously by trace-level degradation of triosephosphate
glycolytic intermediates, glyceraldehyde-3-phosphate (GA3P) and
dihydroxyacetonephosphate (DHAP), and modifies proteins and




one (MGdG) as major adducts (Figures 1B, C). Glo1 suppresses
the steady-state cellular concentration of MG and thereby the
steady-state levels of MG-derived protein and DNA adducts to
low, tolerable levels. In previous studies, it has been shown that
inhibition of Glo1 in tumor cells in vitro leads to the accumulation
of MG, increasing protein and DNA modification (8, 9) and
apoptosis (10–12). Treatment of human tumor cells with cell
permeable Glo1 inhibitor pro-drug, S-p-bromobenzylglutathione
cyclopentyl diester (BBGD)—which delivers the Glo1 competitive
inhibitor, S-p-bromobenzylglutathione (Ki = 160 nM) into cells,
increased the cellular concentration of MG, protein, and DNA
adducts and induced apoptosis (8, 9).2
In this study, we explore the effect of overexpression of Glo1
in the antiproliferative activity of clinical antitumor agents,
the contribution of MG-induced cytotoxicity in cancer
chemotherapy and mechanism of MG increase and cytotoxic
response, and Glo1 expression as a risk predictor on cancer
chemotherapy outcomes in clinical breast cancer.METHODS
Antibodies, Anticancer Drugs,
and Other Reagents
Rat monoclonal anti-Glo1 antibody (SAB4200193) and anti-Rat
IgG-biotin conjugate (B7139) were from Sigma-Aldrich (Poole,
Dorset, UK). Human cytochrome c ELISA kit (QIA74) was
from Oncogene Research Products (San Diego, CA,
USA). Mechlorethamine (C2942) was from Cambridge
Bioscience Ltd. (Cambridge, UK). Mitomycin C (M4287,
from Streptomyces caespitosus), cisplatin (479306), S-
(+)-camptothecin (C9911), doxorubicin (D1515), etoposide
(E1383), paclitaxel (T7402), vincristine (V8879), and
methotrexate (06563) were from Sigma-Aldrich. S-p-
Bromobenzylglutathione cyclopentyl diester was prepared in-
house (8). D-Lactic dehydrogenase (L9636), pepsin (EC 3.4.23.1;
porcine stomach mucosa; P6887), pronase E (EC 3.4.24.31, type
XIV, from Streptomyces griseus; P5147), prolidase (EC 3.4.13.9;
porcine kidney; P6675), and leucine aminopeptidase (EC
3.4.11.2, type VI, porcine kidney, L9776) were from Sigma-
Aldrich. Geneticin (700 µg G-418) was from Fisher Scientific
(Loughborough, UK). The HEK293 cell line (CRL-1573) was
ATCC (Virginia, USA), and vectors pIRES2-GLO1-EGFP and
pIRES2-EGFP were prepared in-house (13).Culture of HEK293 Cells In Vitro
The HEK293 cell line, seeding density 2 × 104 cells cm−2, was
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing phenol red, L-glutamine, and 4,500 mg/l glucose,
supplemented with 10% fetal bovine serum (FBS), 100 U
penicillin, and 0.1 mg/ml streptomycin. pIRES2-GLO1-EGFP
plasmid (Glo1+ vector) and pIRES2-EGFP plasmid (empty
vector) were prepared as described (13). HEK293 cells stablyNovember 2021 | Volume 11 | Article 748698
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and empty vector pIRE2-EGFP using Lipofectamine 2000
according to the manufacturer’s instructions (plasmid DNA:
Lipofectamine 2000, 1:4). After 48 h, cells were subculturedFrontiers in Oncology | www.frontiersin.org 3with G-418 disulfate supplement. Transfected colonies with
GFP fluorescence were selected using a cloning disc (3.2 mm)
and glass cylinder selector (8 mm, 150 µl) and cultured further





FIGURE 1 | Metabolism of methylglyoxal by the glyoxalase pathway, major glycation reactions of methylglyoxal and clinical and investigational antitumor drugs.
(A) Metabolism of methylglyoxal by the glyoxalase pathway. (B) Glycation of arginine residues by methylglyoxal from hydroimidazolone, MG-H1. (C) Glycation of
guanyl moieties of DNA by methylglyoxal from isomeric imidazopurinones, MGdG. (D–G) Molecular structures of antitumor drugs. (D) Alkylating agents:
mechlorethamine, mitomycin C, and cisplatin. (E) Topoisomerase inhibitors: camptothecin, doxorubicin, and etoposide. (F) Antitubulins: paclitaxel and vincristine.
(G) Antimetabolites: methotrexate and glyoxalase 1 inhibitor prodrug, S-p-bromobenzylglutathione cyclopentyl diester (BBGD).November 2021 | Volume 11 | Article 748698
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fivefold increase in Glo1 activity and protein, as previously
reported (16). HEK293 cells stably tranfected with empty and
GLO1+ vectors were incubated for 2 days with and without the
anticancer drugs at the concentrations indicated—diluted from
100 mM stock solution in dimethylsulfoxide (DMSO), except
dimethylformamide (DMF) for cisplatin. The effect on cell
growth was assessed by viable cell number counts, using the
Trypan blue exclusion method and median growth inhibitory
concentrations GC50 deduced. For BBGD, cultures were also
performed under an atmosphere of 3% oxygen as a model of
hypoxia. HEK293 cells were incubated with 15–400 µM MG for
48 h to determine the GC50 of MG and with 131 µM MG for 6,
12, and 24 h with medium replacement and continued culture for
48 h to determine the period of exposure to MG required for
growth arrest and cytotoxicity. Cellular MG concentration and
flux of formation of D-lactate, a surrogate measure of flux of
formation of MG, was assayed as described (17, 18).Preparation of Cellular Protein
Extracts for Proteomics
Protein extracts of total cell cytoplasm, nuclei, mitochondrial
matrix, and intermembrane space and mitochondrial
membranes were prepared from HEK293 cells (3 × 106)
incubated with and without 131 µM MG for 6 h by adaptation
of protocols for subcellular fraction proteomics (19). Protein
abundances were analyzed by label-free high-resolution Orbitrap
mass spectrometry of tryptic digests, as described (20).
For cytoplasmic extracts, cell pellets were suspended in 10 mM
sodium phosphate buffer, pH 7.0, sonicated on ice (110W, 30 s, 4°
C), and membranes sedimented by centrifugation (20,000×g, 30
min, 4°C). An aliquot of protein (300 µg) was washed with argon-
purged water by ultradiafiltration over a 10-kDa cutoff membrane
microspin filter (14,000×g, 20 min, 4°C); 4 cycles of concentration
to 50 µl and 10-fold dilution with water. An aliquot of washed
protein (100 µg) was used in proteomics analysis.
For the nuclear extract, cells were washed in PBS,
resuspended in buffer (0.3 M sucrose, 10 mM MgCl2, 50 mM
Tris-HCl, pH 7.8, and 0.1 mM phenylmethylsulphonyl fluoride
(PMSF); 1 ml, 4°C), homogenized in a Teflon-glass homogenizer,
and centrifuged (1,000×g, 10 min, 4°C). The pellet was
suspended in further buffer without PMSF (0.1 ml) and layered
onto a “sucrose cushion” of 2 M sucrose in the same buffer; 1 ml.
After centrifugation (16,000×g, 20 min, 4°C), the supernatant
was discarded, the pellet of purified nuclei washed twice in PBS,
resuspended in buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2,
0.5 M NaCl, 0.2 mM EDTA, and 20% glycerol; 25 µl) and
incubated for 30 min with gentle rocking at 4°C. Nuclei were
then lysed with 10 passages through an 18-gauge needle, the
lysate centrifuged (9,000×g, 30 min 4°C), and the supernatant
used for proteomics analysis.
For mitochondrial protein extracts, cell pellets were
resuspended in isotonic buffer (25 M sucrose, 5 mM Tris-HCl,
pH 7.5, and 0.1 mM PMSF; 1 ml) and disrupted in a glass-Teflon
homogenizer. Unbroken cells and nuclei were sedimented byFrontiers in Oncology | www.frontiersin.org 4centrifugation (600×g, 15 min, 4°C) and supernatants
centrifuged again (10,000×g, 25 min, 4°C) to collect the pellet
of mitochondria. The mitochondrial pellet was washed once with
isotonic buffer containing 1 mM EDTA, pH 7.5; 1 ml. For the
mitochondrial matrix and intermembrane space protein extract,
samples were suspended in lysis buffer (1 mM dithiothreitol
(DTT) and 10 mM HEPES pH 7.4; 200 µl), incubated at
4°C for 30 min, and then sonicated (110 W, 3 × 30 s,
4°C) and centrifuged (1 h, 120,000×g, 4°C). The supernatant
was transferred to a 3-kDa cutoff filter and washed by
ultradiafiltration at 4°C, concentrating finally to 25 ml and the
washed protein used in proteomics analysis. For the
mitochondrial membrane protein extract, the membrane pellet
was treated with membrane extraction buffer (20 mM Tris-HCl,
pH 7.4; 0.4 M NaCl, 15% glycerol, 1 mM DTT, and 1.5% Triton-
X-100; 0.2 ml) and samples shaken gently at 4°C for 1 h. Samples
were then centrifuged (20,000×g, 4°C, 1 h). The supernatant was
retained and protein washed by ultradiafiltration in 1.5% Triton-
X100. Protein content was quantified with EZQ™ method and
Triton-X100 removed by extraction with ethylacetate (21) before
proteomics analysis.Proteomics Analysis
Protein extracts (100 µg) were reduced by treatment with DTT
(6 ml, 6 mM) in the dark for 30 min at 37°C, and then alkylated by
treatment with iodoacetamide (5.9 µl, 10.8 mM). Residual
iodoacetamide was quenched by further addition of DTT (5.9
ml, 6 mM). Lys-C protease (1 mg/ml, 5 µl) in 500 mM ammonium
bicarbonate, pH 8.0, was added, and samples were incubated for 1
h at 37°C. TPCK-treated trypsin (1 mg/ml, 5 µl) in 1 mM calcium
chloride/500 mM ammonium bicarbonate, pH 8.0, was then
added, and samples were incubated at 37°C for 5 h. An aliquot
of 10% trifluoracetic acid in water (5 µl) was added to stop the
reaction. Samples were then lyophilized to dryness and
resuspended in 0.1% formic acid in water. Processed cell lysate
samples were submitted for a label-free proteomic quantitation
analysis by reversed phase nanoflow liquid chromatography-mass
spectrometry-Orbitrap Fusion mass spectrometer equipped with a
microspray source operating in positive ion mode, as previously
described (18).
For the peptide ion data search, Mascot (Matrix Science,
version 2.5.0) was used against a Homo sapiens database (http://
www.uniprot.org/), with product ions and precursor error mass
±5 ppm and ±0.8 Da and allowance made for six trypsin-missed
cleavages, carbamidomethylated cysteine, MG-H1, and
methionine sulfoxide residues. Only fully tryptic peptide
matches were included. Scaffold (version Scaffold 4.3.2,
Proteome Software Inc.) was used to validate MS/MS peptide
fragmentation and protein identification (false discovery rate
(FDR) <5%) and ≥2 unique peptides, with detection probabilities
assigned using protein prophet algorithm (22). Label-free
quantitation of protein abundances were determined in three
independent biological replicate samples using Progenesis QI for
proteomics 2.0 software (Nonlinear Dynamics, Newcastle, UK).
For the pathway enrichment analysis in transcriptomic andNovember 2021 | Volume 11 | Article 748698
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Database for Annotation, Visualization and Integrated
Discovery v6.8 (https://david.ncifcrf.gov/) (23). KEGG and
REACTOME analyses were used for pathway enrichment
analysis and INTERPRO analysis for enrichment of protein
domains. Pathway and domain enrichment were considered
significant with FDR <0.05.Cancer Bioinformatics Database CCLE
Data on gene copy number and expression (RNA-seq) in human
tumor cell lines were extracted from the Cancer Cell Line
Encyclopedia (CCLE) database (https://portals.broadinstitute.
org/ccle) for 1,040 human tumor cell lines. Correlation analysis
was performed using the R program and Pearson correlation
analysis performed on mRNA copy number expressed as reads
per kilobase million (RPKM). Data for 10,758 genes were
available and a Bonferroni correction applied on outcomes. A
Protein Interaction Network was prepared for 340 genes with
strong positive correlation with Glo1 expression. The gene list
was submitted to STRING (https://string-db.org/) and a network
among them prepared based on “experiments” and “databases”
as active sources with the highest confidence level (interaction
score >0.9). This resulted in a network with 1,617 edges and 322
nodes (18 identifiers could not be mapped) with an average node
degree of 10. The network was clustered using the Markov
Clustering Algorithm with inflation parameter set to three and
the nodes were colored according to the enriched KEGG
pathways indicated.Kaplan-Meier Survival Analysis Database
The Kaplan-Meier plotter analysis tool (http://kmplot.com/
analysis/) was used for the analysis of the impact of Glo1 and
Glo2 expression on overall survival of breast cancer patients
treated with chemotherapy. Correlation analysis was also
performed for expression of Glo1 with PPIL1, CDC5L, and
TRADD in pan cancer database (7,489 multiple types of human
tumor; RNA seq) and breast cancer (n = 4,939, gene chip). The
output variables were number of patients, hazard ratio and upper
quartile survival (months) for low/high gene expression cohorts,
and Logrank p-value (24, 25). Chemotherapy received by patients
in this dataset was doxorubicin, mitomycin C, and alkylating
agents, cyclophosphamide and thiotepa.Statistical Analysis
Data are expressed as mean ± SD or SEM, as indicated. Statistical
analyses were performed with SPSS, version 24. Normality of data
distribution was assessed using Kolmogorov-Smirnov test.
Comparisons between two groups were performed using two-
tailed Student’s t-test for normally distributed data and Mann-
Whitney U test for non-normally distributed data. Differences
between multiple groups with one variable were determined
using one-way ANOVA for normally distributed data and
Kruskal-Wallis test for nonnormally distributed data. CorrelationFrontiers in Oncology | www.frontiersin.org 5analysis used Pearson and Spearman methods for normally
distributed and nonnormally distributed data, respectively.RESULTS
Overexpression of Glyoxalase 1 in HEK-
293 Cells Decreases Antiproliferative
Activity of Clinical Antitumor Drugs
We studied the effect of overexpression of Glo1 on the
antiproliferative, cytotoxic activity of antitumor drugs: alkylating
agents—mechlorethamine, mitomycin C, and cisplatin
(Figure 1D); topoisomerase inhibitors—camptothecin,
doxorubicin, and etoposide (Figure 1E); antitubulins—paclitaxel
and vincristine (Figure 1F); and antimetabolite—methotrexate
(Figure 1G). We found overexpression of Glo1 decreased the
antiproliferative activity for most anticancer drugs. In order of
increasing effect, MDR (fold increase in GC50) was vincristine,
1.3-fold; etoposide, 2-fold; mechlorethamine and methotrexate,
7-fold; paclitaxel, 8-fold; mitomycin C, 15-fold; and doxorubicin,
16-fold (Figures 2A–I and Table 1). MG is the major dicarbonyl
endogenous substrate metabolized by Glo1 (26). This finding
suggests that anticancer drugs may increase steady-state
cellular concentrations of MG to toxic levels as part of their
mechanism of action. To test this, we measured the cellular
concentration of MG in HEK293 cells after treatment for 3 h
with drugs for which Glo1 overexpression produced resistance.
Cellular MG concentration was increased twofold with
mitomycin C, threefold with mechlorethamine and etoposide,
fivefold with doxorubicin and paclitaxel, and eightfold with
methotrexate (Figure 3A). Increased MG concentration is
often linked to inhibition of Glo1, as in the mechanism of
action of BBGD (8) and/or increased formation of MG by
increased glycolysis (18). BBGD increased the endogenous
concentration of cellular MG by fivefold and also had
cytotoxic, antiproliferative activity: GC50 = before 5.12 ±
0.33 µM (n = 18). None of the drugs studied were potent
inhibitors of Glo1 over the concentration range studied
(Supplementary Figure S1). Rather, the increase of MG may
be related to increased flux of formation of MG, as reflected in
increased flux of formation of D-lactate—as surrogate measure
of flux of formation of MG (27). To explore this, we studied the
effect of the 2 × GC50 concentration of anticancer drugs on the
flux of formation of D-lactate. The flux of formation of D-
lactate over the initial 24 h of drug treatment was increased ca.
twofold by treatment with mechlorethamine, doxorubicin,
paclitaxel, and methotrexate (Figure 3B). Increased D-lactate
often reflects a proportionate increase inmetabolism of glucose
through glycolysis (18, 28). To test this, wemeasured the flux of
consumption of glucose by HEK293 cells in the initial 24 h of
treatment with doxorubicin and found that the flux of glucose
consumption was indeed increased twofold, proportionate to
increase of flux of D-lactate (Figure 3C). This suggests
doxorubicin increased the cellular concentration of MG by
increasing the flux of formation of MG as a consequence of the
increased of flux of glucose metabolism through glycolysis.November 2021 | Volume 11 | Article 748698
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and the flux of glucose metabolism through glycolysis and hence
formation of MG is increased in hypoxia. Expression of Glo1 is
also downregulated in hypoxia inducible factor-1a (29). We
explored the effect of low oxygen concentration, an atmosphere
of 3% oxygen, compared with culture under normoxicFrontiers in Oncology | www.frontiersin.org 6atmosphere containing 20% oxygen on MG-related metabolism
and potency of BBGD. In 3% oxygen atmosphere, the flux of
glucose consumption and formation of D-lactate were increased
twofold and the expression of Glo1 was decreased by 69%. The
combined effect of increased MG formation and decreased Glo1
expression was associated with a concomitant increase inA B C
FD E
IG H
FIGURE 2 | Suppression of antiperoxidative activity of clinical antitumor drugs by overexpression of glyoxalase. Color code for blue data points and curve: blue,
empty vector transfected; red, Glo1+ vector transfected. (A) Mechlorethamine. GC50 = 1.90 ± 0.11 µM, n = 1.20 ± 0.09 (empty vector) and GC50 = 12.70 ± 0.90
µM, n = 1.75 ± 0.26 (Glo1+; sevenfold resistance). (B) Mitomycin C. GC50 = 174 ± 29 nM, n = 0.83 ± 0.12 (empty vector) and GC50 = 2,541 ± 360 nM, n = 0.39 ±
0.03 (Glo1+; 15-fold resistance). (C) Cisplatin. GC50 = 3.17 ± 0.35 µM, n = 0.92 ± 0.04 (empty vector) and GC50 = 0.73 ± 0.05 µM, n = 0.89 ± 0.07 (Glo1+; 0.2-fold
resistance). (D) Camptothecin. GC50 = 21.8 ± 2.2 nM, n = 1.28 ± 0.15 (empty vector) and GC50 = 37.6 ± 3.3 nM, n = 1.12 ± 0.12 (Glo1+; twofold resistance).
(E) Doxorubicin. GC50 = 3.54 ± 0.28 nM, n = 0.71 ± 0.05 (empty vector) and GC50 = 55.9 ± 3.4 nM, n = 1.24 ± 0.10 (Glo1+; 16-fold resistance). (F) Etoposide.
GC50 = 500 ± 32 nM, n = 1.41 ± 0.19 (empty vector) and GC50 = 1,170 ± 169 nM, n = 1.06 ± 0.17 (Glo1+; twofold resistance). (G) Paclitaxel. GC50 = 6.8 ± 1.0 nM,
n = 1.07 ± 0.17 (empty vector) and GC50 = 56.4 ± 7.2 nM, n = 0.55 ± 0.04 (Glo1+; eightfold resistance). (H) Vincristine. GC50 = 63.4 ± 5.2 nM, n = 1.04 ± 0.10
(empty vector) and GC50 = 83.7 ± 3.3 nM, n = 1.57 ± 0.10 (Glo1+; 1.3-fold resistance). (I) Methotrexate. GC50 = 4.02 ± 0.35 nM, n = 1.10 ± 0.10 (empty vector)
and GC50 = 28.5 ± 0.9 nM, n = 0.81 ± 0.02 (Glo1+; sevenfold resistance). Data were fitted by nonlinear regression to the dose-response equation: Viable cell
number (% of control) = 100 × GC50
n/(GC50
n + [Drug]n), solving for GC50 and n (logistic regression coefficient) and plotting the outcome dose-response curves given
(six drug concentrations in triplicate; n = 18). GC50 values are summarized (Table 1). Data for doxorubicin and paclitaxel and evidence of increased Glo1 protein in
the Glo1+ cell line have been published previously (16).November 2021 | Volume 11 | Article 748698
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(Figures 3D–G).
Mechanism of the Antiproliferative,
Cytotoxic Activity of Methylglyoxal in
HEK293 Cells In Vitro—Early-Stage
Proteomic Response to MG-Induced
Cytotoxicity
To explore the mechanism of cytotoxicity of MG, we initially
characterized the potency and time course of commitment to the
antiproliferative response inHEK293cells in vitro. TheGC50 ofMG
was 131± 19.1 µM(Figure 3H) anddecrease of viability ofHEK293
cells incubated with 131 µM MG reached maximum effect after
exposure to MG for 12 h (Figure 3I). We studied cytochrome c
increase in the cell cytosol as an indicator of activation of the
mitochondrial, intrinsic pathway of apoptosis (30). The cytosolic
concentration of cytochrome cwas increased from3 to6 hwithMG
treatment anddecreased thereafter (Figure3J).We found themajor
MG-derived glycation adduct of cell protein, MG-H1 residues,
increased rapidly within the initial 1.5 h, remained high until 6 h,
and decreased to approach basal levels by 12 h of exposure to MG
(Figure 3K).We then investigated the proteomic response in early-
stage commitment to apoptosis by a label-free quantitative
proteomics study of subcellular fractional proteome HEK293 cells
treated with and without 131 µM MG for 6 h, examining total
cytoplasmic and thereafter nuclear, mitochondrial matrix and
intermembrane space, and mitochondrial membrane proteomes
—including proteins with MG-H1 modification. Total protein
counts detected, detected with MG-H1 modification and changed
in abundance in all replicates of control and MG-treated cells are
summarized (Table 2).
For the cytoplasmic extract, pathway enrichment analysis of
proteins with decreased abundance with MG treatment showed
over-representation of proteins in the ribosome, spliceosome,
RNA transport, and proteasome metabolic pathways (Table 3).
Sixteen proteins of the spliceosome were detected with MG
modification (Table 4). For the nuclear extract, proteins
decreased were enriched in the major mRNA splicing pathway.
In the mitochondrial matrix and intermembrane space andFrontiers in Oncology | www.frontiersin.org 7mitochondrial membrane fractions, there were major protein
abundance decreases—particularly in the mitochondrial
membrane where 116 of 168 proteins detected were decreased
in abundance. Pathway enrichment analysis of these proteins
revealed enrichment in two key mitochondrial pathways:
respiratory electron transport and formation of ATP by
chemiosmotic coupling (Table 3). There were no MG
modifications detected of mitochondrial permeability transition
pore (mPTP), respiratory electron transport, or formation of
ATP by chemiosmotic coupling component proteins. Overall,
the early-stage proteomic response in MG-induced cytotoxicity
in HEK293 cells was characterized by a depletion of the RNA
splicing proteins and mitochondrial respiratory electron
transport chains, suggesting damage of MG to the spliceosome
and activation of the mitochondrial apoptotic pathway.
Association of Methylglyoxal Metabolism
With the Spliceosome in Human Tumor
Cell Lines and Clinical Human Tumors
Having discovered the spliceosome as a target of MG-induced
toxicity, we assessed if expression of Glo1 may be linked to
protection of the spliceosome in human tumor cell lines and
clinical human tumors. An indication of this would be positive
correlationof expressionof spliceosomeproteinswith expressionof
Glo1. To explore this in human tumor cell lines, we accessed RNA-
seq data from the CCLE—a database of gene expression and gene
copy number estimates for 1,040 human tumor cell lines (https://
portals.broadinstitute.org/ccle). Data were available from 1,010 cell
lines of different tumor types. Correlation analysis revealed 4,021
genes correlating significantlywithGlo1: 3,032 correlated positively
with Glo1 with correlation coefficients (r) in the range 0.134–0.568
and 989 genes correlated negatively with Glo1 with r in the range
−0.535 to −0.134 (Supplementary Table S12). Two of the top 4
genes rank ordered by r-valuewere genes of the spliceosome: PPIL1
(first, r=0.57) (Figure4A) andCDC5L (fourth, r=0.52).Therewas
also a strong positive correlation ofGlo1mRNAcopy number with
GLO1genecopynumber (r=0.53), suggesting that increasedGLO1
copy number may contribute to increased Glo1 mRNA
(Figure 4B). Genes with expression correlating positively withTABLE 1 | Median growth inhibitory concentration of anticancer drugs of HEK-293 cells in vitro—effect of overexpression of glyoxalase 1.
Anticancer drug GC50
Empty vector Glo1+ Fold MDR
Alkylator Mechlorethamine (µM) 1.90 ± 0.11 12.70 ± 0.90*** 7
Mitomycin C (nM) 174 ± 29 2541 ± 360*** 15
Cisplatin (µM) 3.17 ± 0.35 0.73 ± 0.05*** 0.2
Topoisomerase inhibitor Camptothecin (nM) 21.8 ± 2.2 37.6 ± 3.3*** 2
Doxorubicin (nM) 3.54 ± 0.28 55.9 ± 3.4*** 16
Etoposide (nM) 500 ± 32 1170 ± 169*** 2
Antimicrotubule Paclitaxel (nM) 6.8 ± 1.0 56.4 ± 7.2*** 8
Vincristine (nM) 63.4 ± 5.2 83.7 ± 3.3*** 1.3
Antimetabolite Methotrexate (nM) 4.02 ± 0.35 28.5 ± 0.9*** 7November 2021 | Volume 11 | ArtHEK293 cells with stable transfection by empty vector (Empty vector) or vector producing four- to fivefold increased expression of Glo1 (Glo1+) were incubated with and without treatment
with anticancer drugs, six different concentrations in triplicate, for 48 h. The median growth inhibitory concentration of the drug, GC50, was deduced by nonlinear regression of viable cell
number (V) on drug concentration for the dose-response equation, V = 100 GCn50=(GCn50 + ½Drugn ), solving for GC50 and logistic regression coefficient (n). n values are omitted for
brevity. Significance: ***p < 0.001 (Student’s t-test).icle 748698
Alhujaily et al. Glyoxalase 1-Linked Multidrug Resistance and the SpliceosomeGlo1were analyzed forpathway enrichmentanalysis, limiting genes
for which correlation coefficient r2 ≥ 0.10, thereby accounting for
≥10% variation inGlo1 expression. For the 340 genes submitted for
analysis, pathway enrichment analysis revealed four pathways:
spliceosome, RNA transport, cell cycle, and DNA replicationFrontiers in Oncology | www.frontiersin.org 8(Table 5). This is also illustrated in an interaction network
diagram (Figure 4D). Increased expression of Glo1 may provide
a protective shield of the spliceosome against MG glycation
permissive for tumor growth. DNA replication in the cell cycle is
dependent on pre-mRNA splicing and accurate alternative splicingA
B C
D E GF
H I J K
FIGURE 3 | Induction of cellular dicarbonyl stress by antitumor drugs and mechanism methylglyoxal-induced cytotoxicity. (A) Increase in cellular MG in HEK293 cells
treated with antitumor drugs for 3 h. Control (no drug added) and ca. 2 × GC50 concentration in nontransfected cells: mechlorethamine (MCH, 4.8 µM), mitomycin C
(MITC, 316 nM), doxorubicin (DOX, 6.0 nM), etoposide (ETOP, 323 nM), paclitaxel (PTX, 21 nM), methotrexate (METX, 7.6 nM), and BBGD (7.4 µM). Data are mean
± SEM (p < 0.001; one-way ANOVA; n = 3 except n = 4, 5, and 6 for DOX, METX, and MITC, respectively). (B) Flux of formation of D-lactate (surrogate for flux of
MG) and (C) flux of glucose consumption incubated in vitro with and without investigational agent and drugs indicated. Cells were incubated for 24 h with and
without 2 × GC50 concentration. Data are mean ± SEM (n = 3). (D–G) Effect of hypoxia on formation and metabolism of methylglyoxal and antiproliferative activity of
BBGD. (D–F)) Flux of glucose consumption and formation of D-lactate and Glo1 activity of HEK293 cells incubated for 72 h in 20% and 3% oxygen, models of
normoxia and hypoxia, respectively. Data are mean ± SEM (n = 3). (G) Dose-response curve for BBGD. The GC50 values for BBGD under normoxic and hypoxic
conditions were 5.12 ± 0.33 µM and 0.085 ± 0.010 mM, respectively (N = 18). (H) Dose-response curve for MG-treated HEK293 cells. GC50 131 µM ± 19.1, with
logistic regression coefficient n = 0.70 ± 0.05 (N = 18). (I) Effect of duration of exposure to MG on antiproliferative activity in HEK293 cells in vitro. Cells were
incubated with 131 µM MG. Data are mean ± SD (n = 3). (J) Release of cytochrome c from mitochondrial in early-stage MG-induced toxicity. HEK293 cells were
incubated with and without MG in vitro and cytosolic cytochrome c assayed by ELISA. Key: hollow bars, control; solid bars, +131 µM MG. Data are mean ± SD (n =
3). Significance: *p < 0.05, **p < 0.01, and ***p < 0.001 with respect to control (t-test). (K) Early-stage accumulation of glycated modified during MG-induced
cytotoxicity of HEK293 cells in vitros. Key: open symbols, control; filled symbols, +131 µM MG. Data are mean ± SD (n = 3).November 2021 | Volume 11 | Article 748698
TABLE 2 | Subcellular fractional proteomics of HEK293 cells treated with methylglyoxal.
Protein count with MG-H1 modification (fold change)
detected Increased abundance Decreased abundance
493 41 (1.2- to 14.0-fold) 69 (0.05- to 0.91-fold)
120 5a 1a
ne s 42 2b 1b
26 2 9
ry Ta onse element-binding protein (Mondo A, 263-fold), protachykinin-1 (21-fold),
5-fold se—ABHD14A (0.08-fold). bProteins with MG-H1 modification were as follows:
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9, RPL31, RPL32, RPL34, RPL35, RPL36, RPL38, RPL6, RPL7, RPL8,
RPS20, RPS25, RPS27, RPS27L, RPS28, RPS29, RPS3, RPS6,
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D3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD12, PSME1, PSME2,
RPA1, SNRPD1
DHB, UQCR10, UQCRB
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Total protein count (fold change)
Total detected Increased abundance Decreased abundance Total
4,091 1,185 (1.2- to 30.5-fold) 121 (0.03- to 0.91-fold)
2,060 48 (1.2- to 263-fold) 59 (0.02- to 0.78-fold)
936 16 (1.4- to 49.3-fold) 132 (0.02- to 0.79-fold)
168 9 (2.1–9.6) 116 (0.01–0.69)
S1–S11). aProteins with MG-H1 modification were as follows: abundance increase—carbohydrate-resp
thamide biosynthesis protein-1 (7-fold), and mitochondrial enoyl-CoA hydratase (2-fold); abundance decre
ghtfold) and metastasis suppressor protein-1 (sevenfold); abundance decrease—B-cell CLL/lymphoma 9-li
d control.







0.65 ± 0.17 FAU, MRPL1, MRPL11, MRPL13, MRPL27, MRPL3, MRPS11, MR
RPL18, RPL21, RPL22, RPL22L1, RPL23, RPL23A, RPL26, RPL2




0.66 ± 0.18 BUD31, CCDC12, CTNNBL1, DDX23, DDX39B, DDX5, DHX15, D
MAGOH, MAGOHB, PPIE, PPIH, PRPF19, PRPF3, PRPF38B, PR
SF3B3, SF3B5, SF3B6, SNRNP40, SNRNP70, SNRNP200, SNW
.1 2.3 ×
10−10
0.66 ± 0.14 CYFIP1, DDX39B, EEF1A1, EEF1A2, EIF1, EIF2S1, EIF3C, EIF3CL
ELAC2, GEMIN4, GEMIN5, MAGOH, MAGOHB, NMD3, NUP133,
RANGAP1, RGPD8, RPP30, SUMO1, SUMO2, SUMO3, TACC3,
.3 9.7 ×
10−5




0.52 ± 0.21 CPSF1, HNRNPUL1, LSM7 MAGOHB, PCBP2, PTBP1, SF3B4, S
2.1 1.3 ×
10−4
0.18 ± 0.08 COX5A, COX5B, COX7C, CYCS, NDUFA4, NDUFA5, NDUFB10, S
8.6 2.8 ×
10−2
0.24 ± 0.12 ATP5F1A, ATP5F1B, ATP5F1D, ATP5H, ATP5PO
eased abundance in subcellular fractional proteomes of HEK293 cells treated with MG, compared with con























Alhujaily et al. Glyoxalase 1-Linked Multidrug Resistance and the Spliceosome(31). Analysis of structural domains enriched in these proteins
showed highest enrichment of chaperonin TCP-1, conserved site
(Table 6). This was previously found to be enriched in proteins
susceptible to modification by MG (18).
For negative correlation with Glo1, there were only eight genes
with r2 ≥ 0.10. These were three pseudogenes and two long
noncoding RNAs; N-acetylglucosamine-1-phosphate transferase
subunit gamma (GNPTG)—part of a complex targeting lysosomal
hydrolases to the lysosome and Tapasin (TAPBL) which mediates
binding of newly assembled major histocompatibility complex
class I molecules and the transporter associated with antigen
processing (TAP), both r2 = 0.11; and tumor necrosis factor
receptor type 1-associated death domain protein (TRADD)—an
adaptor protein involved in receptor-mediated apoptosis, r =
−0.35 (Figure 4C). This supports the link of increased Glo1
expression with decreased risk of apoptosis, through decreased
risk of MG-induced apoptosis.
For clinical translation,we performed correlation analysis ofGlo1
expression with PPIL1, CDC5L, and TRADD in a pan cancer
database (7,489 multiple types of human tumor; RNA seq) and
breast cancer (n = 4,939, gene chip) of the KM Plotter database—a
compendium of gene expression and survival data of cancer patients
receiving chemotherapy and other treatments. Correlation analysis
withGlo1 expression gave the following: pan cancer—PPIL1, r=0.59
and CDC5L, r = 0.58 (p < 1 × 10−6) and TRADD, r = −0.17 (p = 5 ×
10−4); and for breast cancer—PPIL1, r = 0.55; CDC5L, r = 0.26 and
TRADD, r = −0.20 (p < 1 × 10−6). This indicates that there was a
similar correlation of Glo1 expression in human clinical tumors as in
the human tumor cell lines of the CCLE.
Glyoxalase 1 Expression as a Risk
Predictor of Cancer Patient Survival
With Chemotherapy Treatment
To explore the clinical relevance of baseline Glo1 expression in
clinical cancer chemotherapy, we investigated association of
Glo1 expression with cancer patient survival receivingFrontiers in Oncology | www.frontiersin.org 10chemotherapy in the KM Plotter database. For chemotherapy
(any), analysis had adequate statistical power for Glo1 expression
and patient survival for breast cancer without classification of
tumor stage, grade, type, and genotype. The one exception was
for analysis of the HER2-negative genotype. For breast cancer
patients, high expression of Glo1 was associated with poor
survival, with HR = 1.82 (logrank p < 0.001, n = 683)
(Figures 5A, D). This effect was also present in HER2-negative
breast cancer. For HER2-negative breast cancer, high expression
of Glo1 was associated with poor survival, with HR = 2.02
(logrank p < 0.001, n = 531) (Figures 5B, E). The upper
quartile survival was low Glo1 expression, 173.7 months, and
high Glo1 expression, 63.5 months in both survival analysis
datasets; 64% decreased survival. In contrast, there was no
significant association of Glo2 (gene HAGH) expression with
breast cancer patient survival (Figure 5C). For the entire dataset
of breast cancer patients in the KM Plotter database, the
expression of Glo1 was increased in cancer compared with
nonmalignant breast tissue (Figure 5F).DISCUSSION
Overexpression of Glo1 suppressed the antiproliferative activity of
multiple classes of antitumor drugs. Drug-induced increase of
cellular MG to cytotoxic levels contributed to the mechanism
of action of antitumor drugs, linked to increased formation of MG
by off-target drug-induced increased glycolysis. Alkylating agents
such as mechlorethamine and topoisomerase inhibitors lead to
decreased cellular NAD+ in early-stage of treatment, decreasing
glycolysis at the glyceraldehyde-3-phosphate dehydrogenase-
catalyzed step and consequently increasing cellular GA3P and
DHAP and formation of MG (32–34). Doxorubicin also increases
glucose metabolism by increasing expression of glucose
transporter GLUT1 and hexokinase-2 (35). Paclitaxel stabilizes
microtubules, decreasing free tubulin concentration; the latter
increasing mitochondrial voltage-dependent anion channel
(VDAC) activity and thereby in situ activity of hexokinase
and glycolysis (36). Methotrexate activates AMPK and
thereby stimulates glycolysis by activating phosphorylation of
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (37).
Increased formation of MG by antitumor agents is likely most
marked in S phase of the cell cycle when expression of glycolysis
enzymes is highest (38). Indeed, early studies of MG-induced
apoptosis suggested cell death occurs in this phase (39). The three-
to fivefold increase of MG concentration in the total cell
population induced by anticancer drugs may underestimate that
of S phase cells, accounting for ca. 20% of the cell population (40).
Although anticancer drug-induced increase of MG to
cytotoxic levels contributing to the antiproliferative mechanism
of action likely explains the susceptibility of the anticancer drugs
to Glo1-mediated MDR, the increased cellular concentration of
MG assayed after exposure of HEK293 cells to anticancer drugs
for 3 h was not strongly correlated to drug-associated fold of
Glo1-linked MDR. The latter is expected to correlate with peak
MG concentration induced by drug treatment. Increase in MGTABLE 4 | Spliceosome proteins detected with MG-H1 modification in HEK293
cells treated with methylglyoxal in vitro.
No Gene Name of protein
1 ACIN1 Apoptotic chromatin condensation inducer 1
2 DHX15 DEAH-box helicase 15
3 FUS RNA-binding protein FUS
4 HNRNPK Heterogeneous nuclear ribonucleoprotein K
5 HNRNPM Heterogeneous nuclear ribonucleoprotein M
6 HNRNPU Heterogeneous nuclear ribonucleoprotein U
7 HSPA1B Heat shock protein family A member 1B
8 HSPA1L Heat shock protein family A member like
9 HSPA2 Heat shock protein family A member 2
10 HSPA8 Heat shock protein family A member 8
11 RBM22 Heat shock protein family A member 1B
12 SNRPD2 Small nuclear ribonucleoprotein Sm D2
13 THOC1 THO complex 1
14 TMEM231 Transmembrane protein 231
15 TRA2A Transformer 2 alpha homolog
16 U2AF1L5 Splicing factor U2AF 35 kDa subunit-like proteinSpliceosome proteins detected with MG-H1 modification of proteomic datasets reported
in Table 2.November 2021 | Volume 11 | Article 748698
Alhujaily et al. Glyoxalase 1-Linked Multidrug Resistance and the Spliceosomeconcentration in response to anticancer drug treatment is
expected to increase rapidly and maximize concomitant with
increase in the concentration of cellular triosephosphates, as
found previously at 3 h for mechlorethamine-treated leukemia
L1220 cells (33). However, the time of peak MG concentration
likely varies, and so maximal drug-induced MG concentration
was not captured herein. Rather, herein, we identified that many
anticancer drugs increase cellular MG to cytotoxic levels.Frontiers in Oncology | www.frontiersin.org 11There was an exception to Glo1 expression-linked MDR:
enhanced antiproliferative and cytotoxic activity of cisplatin by
overexpression of Glo1. Cisplatin is a DNA-alkylating agent,
mainly binding and crosslinking N7 sites of deoxyguanosine
(dG), intrastrand crosslink, cis-Pt(NH3)2d (pGpG) (41). MG is a
major precursor of endogenous DNA modification in vivo
forming imidazopurinone MGdG, in slow dynamic
equilibrium with MG; degradation half-life 12 h at pH 7.4 andA B C
D
FIGURE 4 | Correlation of glyoxalase 1 expression in human tumor cell lines and clinical human breast cancer with chemotherapy treatment—a negative survival
factor. (A–C) Correlation of Glo1 expression in the CCLE human tumor cell line database. (A) Correlation of Glo1 with PPIL1 (r = 0.57). (B) Correlation of Glo1 with
GLO1 CNV (r = 0.53). (C) Correlation of Glo1 with TRADD (r = −0.35). (D) Protein interaction network among genes with expression highly correlated positively with
GLO1 in the CCLE human tumor cell database. Several enriched KEGG pathways are highlighted and their significance indicated (false discovery rate (FDR)). For
clarity, only the largest connected component is shown.November 2021 | Volume 11 | Article 748698
Alhujaily et al. Glyoxalase 1-Linked Multidrug Resistance and the Spliceosome37°C. Cellular DNA content of MGdG is ca. 1:20,000 dG.
Cisplatin may interact favorably with the 6,7-dihydro-6,7-
dihydroxy-6/7-methylimidazo moiety of MGdG and thereby be
inactivated, explaining why increase of Glo1 with decrease of MG
and MGdG increases the cytotoxicity of cisplatin.
A feature of MG metabolism in HEK293 cells was the impact
of hypoxia, producing increased flux through anaerobic
glycolysis with a twofold increased formation of MG and
threefold decrease in activity of Glo1. These responses
synergize to increase cellular MG and likely contribute to the
60-fold increased potency of BBGD for induction of cytotoxicity
in HEK293 cells with an atmosphere of 3% oxygen versus 20%
oxygen. Cell permeable Glo1 inhibitors thereby may have greater
potency in hypoxic than normoxic tumors in vivo, assuming the
downregulation of Glo1 by hypoxia is maintained. In some
instances, however, hypoxia conditioning of tumors leads to
dysregulation and increased Glo1 expression in hypoxia (42).
From the studies herein, dysregulation of Glo1 in tumor hypoxia
may contribute to MDR in cancer chemotherapy and increased
tumor survival.
Herein, we provided the first examination of the early-stage
proteomic response to MG-induced cytotoxicity, finding protein
abundance decrease enriched in pathways involving ribosome,
spliceosome, RNA, and proteasome pathways. Ribosomal
pathways of protein synthesis contain multiple proteins
susceptible to MG modification, as found in studies of
cytoplasmic protein extracts of endothelial cells (18).
Ribosomal proteins may suffer preferential modification by
MG and thereafter increased degradation. This study is the
first to implicate the spliceosome in the mechanism of MG
cytotoxicity. There was a decreased abundance of 95 ribosomalFrontiers in Oncology | www.frontiersin.org 12and spliceosomal proteins in MG-induced cytotoxicity (Table 3).
Dysfunction of the spliceosome is induced by multiple classes of
anticancer drugs (43). There was a 48% decrease of major
pathway of RNA splicing in nuclear extracts. Further
associations between MG metabolism and the spliceosome
were the positive correlation of Glo1 expression with
expression of spliceosomal genes in human tumor cell lines
and clinical human tumors and MG modification detected on
16 spliceosome pathway proteins. The arginine-rich domains of
serine/arginine-rich splicing factors, SRSFs 1–12, may be targets
in MG-induced cytotoxicity. SRSF1, SRSF4, SRSF5, and SRSF6
were decreased by MG-induced toxicity in HEK393 cells herein.
Dysregulation of these splicing factors has been implicated in
cancers of the breast, lung, and colon; melanoma; and acute
myeloid leukemia (44). Activity of Glo1 inhibitor prodrugs may
deserve investigation against these tumor types.
In selection of the duration of exposure of HEK293 cells to
MG to capture the proteomic signature for commitment to
apoptosis, we determined the minimum duration of incubation
of HEK293 cells with MG for decrease in cell viability. We
incubated cells with MG for varying periods, washed out residual
MG and then continued incubations for 48 h for apoptosis to
fully develop and decrease in viable cell number. For treatment
with the GC50 concentration of MG, the minimum exposure
time to decrease cell viability by 50%—complete response—was
incubation for 12 h. To capture cells at the midpoint of induction
of apoptosis, we therefore incubated cells with MG for 6 h
(Figure 3I). Analysis of total cell protein glycation by MG at
6 h also showed that this was the time point of maximum
MG-derived glycation adduct, MG-H1, content which facilitated




Spliceosome 20 7.0 3.4 ×
10−9
CDC5L, HNRNPA1, HNRNPA3, HNRNPC, HNRNPK, LSM2, LSM3, LSM5, MAGOH, MAGOHB, PPIL1, PRPF4,
RBMXL1, SNRNP40, SNRPB, SNRPC, SNRPD1, SNRPE, SNRPG, SRSF3
RNA
transport
22 6.0 3.4 ×
10−9
DDX20, EIF1AX, EIF2S1, EIF4E, GEMIN5, GEMIN6, KPNB1, MAGOH, MAGOHB, NDC1, NUP35, NUP37, NUP43,
NUP54, NUP107, NUP153, NUP155, RPP40, SUMO1, SUMO2, XPO1, XPO5
Cell cycle 19 7.2 3.4 ×
10−9
CCNB1, CCNB2, CCNE2, CDC25C, CDC27, CDC7, CDK1, DBF4, HDAC2, MAD2L1, MCM3, ORC2, ORC3, ORC4,
PTTG1, SKP1, SKP2, PRIM2, TTK
DNA
replication
10 12.7 1.2 ×
10−6
DNA2, MCM3, POLA1, POLE2, PRIM2, RFC2, RFC3, RFC4, RFC5, RPA2
Proteasome 6 6.4 0.037 PSMD12, PSMA4, PSMD14, PSMB3, PSMC1, PSMB1Pathway enrichment analysis was performed for 340 genes correlating positively with Glo1 RNA copy number in the CCLE database with r2 ≥ 0.1 using the KEGG database; data from
1,010 tumor cell lines for 10,758 genes, applying a Bonferroni correction of 10,758 (Supplementary Table S12). Statistical threshold criterion was FDR <0.05. Genes unrecognized in
KEGG were pseudogene (2), antisense RNA (7), microRNA (2), long noncoding RNA (4), other intronic RNA (1), and uncharacterized proteins (1). Genes highlighted in bold are those
encoding for proteins that were decreased in the early-stage proteomic response to MG-induced cytotoxicity.TABLE 6 | Pathway enrichment of protein domains in genes with expression correlating positively with glyoxalase 1 expression in tumor cell lines of the CCLE.
Protein domain Count Bonferroni p-value FDR Genes
Chaperonin TCP-1, conserved site 8 7.1 × 10−9 1.8 × 10−8 CCT2, CCT3, CCT4, CCT5, CCT6A, CCT7, CCT8, TCP1
Ribonucleoprotein LSM domain 8 1.9 × 10−5 4.8 × 10−5 LSM2, LSM3, LSM5, SNRPB, SNRPD1, SNRPD2, SNRPE, SNRPG
Importin-beta, N-terminal 6 4.0 × 10−3 9.8 × 10−3 CSE1L, IPO11, IPO7, KPNB1, XPO1, XPO5Genes with expression correlating positively with Glo1 with correlation coefficient r2 ≥ 0.10 were analyzed for protein domain enrichment analysis. For the 340 genes submitted for analysis,
protein domain enrichment analysis was performed by INTERPRO in the Database for Annotation, Visualization and Integrated Discovery v6.8 (https://david.ncifcrf.gov/) (23). Threshold
criterion for significance: FDR <0.05.November 2021 | Volume 11 | Article 748698
Alhujaily et al. Glyoxalase 1-Linked Multidrug Resistance and the Spliceosomecytotoxicity was also characterized by a profound loss of proteins
of the mitochondrial chemiosmotic coupling of ATP formation
and respiratory electron transport, disabling cellular metabolic
energy and respiration pathways. It has been proposed that MG
activates the intrinsic apoptotic pathway by modification of the
mPTP complex of proteins, a high conductance channel in
mitochondria (45, 46). MG modification was not detected on
any mPTP proteins herein, and these proteins were not highly
correlated with Glo1 in the CCLE and clinical tumor gene
expression. This suggests that the loss of mitochondrial
proteins may be secondary to dysregulation of the spliceosome
in MG-induced apoptosis (47).
The clinical relevance of the metabolism of MG was
investigated in cancer patients treated with chemotherapy. We
found a marked, 64% decreased overall survival with high
expression of Glo1. This is the first time clinical expression of
Glo1 in tumors has been linked to survival in clinical cancer
chemotherapy. Removal of MG by Glo1 was key to this effect as
there was no similar association with expression of Glo2 (gene
HAGH). The clinical endpoint used herein, overall patient
survival, is a well-defined and robust endpoint. Our findings
implicate expression of Glo1 in human breast cancer as a factor
with major impact on patient survival. The effect was found in aFrontiers in Oncology | www.frontiersin.org 13cohort that had mainly HER2-negative genotype, representing
ca. 60% breast cancers with often poor cancer chemotherapy
outcomes (48). Application of Glo1 inhibitors for relief of Glo1-
linked MDR may be a beneficial adjunct treatment for breast
cancer treatment by chemotherapy.
Previous studies have shown that cytotoxicity of antitumor
drugs in drug-resistant cell lines was enhanced by cotreatment
with BBGD (49) and treatment of tumor-bearingmice with BBGD
decreased tumor growth, including tumors difficult to treat with
current clinical antitumor drugs (8, 49–51). Adjunct chemotherapy
with Glo1 inhibitor may improve treatment outcomes in clinical
cancer chemotherapy, particularlywhere high expression ofGlo1 is
a risk predictor of poor survival outcome.
We conclude that MG-mediated cytotoxicity is a common
contributor to the cancer chemotherapeutic response, stimulated
by off-target effect of anticancer drugs on glycolysis. Enhanced in
hypoxia relevant to clinical tumors, its clinical impact has likely
been hitherto under-appreciated. MG-mediated cytotoxicity
involves activation of the intrinsic apoptotic pathway with
targeting of the spliceosome for MG modification. Conversely,
Glo1 is a common mediator of MDR in cancer chemotherapy.
Glo1-mediated MDR has a major role in poor survival outcomes
in breast cancer which may be countered by clinical developmentA B C
D E F
FIGURE 5 | Glyoxalase 1 expression is a negative survival factor in clinical human breast cancer with chemotherapy treatment. Association of baseline Glo1
expression with overall survival in patients with breast cancer treated with chemotherapy (from the KM Plotter database). Glo1 expression in breast cancers of all
genotypes: (A) Kapan-Meier survival analysis and (D) butterfly plot of breast cancers of low (black dots) and high (red dots) Glo1 expression (n = 683). Glo1
expression in patients with HER2-negative tumors: (B) Kapan-Meier survival analysis and (E) butterfly plot of breast cancers of low (black dots) and high (red dots)
Glo1 expression (n = 531). (C) Kapan-Meier survival analysis for Glo2 expression in breast cancers of all genotypes (n = 683). (F) Glo1 expression in normal breast
tissue and breast cancers. Data are median (lower – upper quartile); normal, n = 3778, cancer, n = 4667. Significance: **P < 0.01; Mann-Whitney U test. For the low
and high gene expression cutoff, the “Autoselect best cutoff” feature in the KM Plotter was used. This computes survival outcomes for all possible cutoff values
between lower and upper quartiles of Glo1 expression and selects the cutoff for FDR below the threshold value (0.05) and minimum p-value (24).November 2021 | Volume 11 | Article 748698
Alhujaily et al. Glyoxalase 1-Linked Multidrug Resistance and the Spliceosomeof Glo1 inhibitors. Glo1 is an established druggable target (8, 49,
51). Future clinical translation of cell permeable Glo1 inhibitors
as adjunct chemotherapy may improve overall survival in breast
cancer and other cancers with high Glo1 expression.DATA AVAILABILITY STATEMENT
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